Aviance Capital Partners’s ARK Genomic Revolution ETF ARKG Stock Holding History

Aviance Capital Partners’s Portfolio ARKG Stock Details ARKG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-10,000	Closed	-$341K	–	251
2023 Q2	$341K	Hold	10,000	–	–	0.07%	205
2023 Q1	$301K	Hold	10,000	–	–	0.07%	218
2022 Q4	$282K	Hold	10,000	–	–	0.07%	233
2022 Q3	$329K	Buy	+10,000	New	+$367K	0.08%	198
2021 Q4	–	Sell	-3,600	Closed	-$269K	–	253
2021 Q3	$269K	Sell	3,600 -6,850	-66%	-$575K	0.05%	229
2021 Q2	$967K	Buy	10,450 +50	+0.5%	+$4.25K	0.17%	145
2021 Q1	$923K	Buy	+10,400	New	+$1.03M	0.18%	147

Other funds holding ARKG

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

MMEA

Main Management ETF Advisors San Francisco, California $2.68B AUM 24.27% 1-Year Est. Return

Aviance Capital Partners's ARKG Position: Q3 2023 in Review

Aviance Capital Partners sold out of ARK Genomic Revolution ETF (ARKG) in Q3 2023, closing a stake of 10,000 shares — an estimated $341K sold.

Aviance Capital Partners first reported a position in ARKG in Q1 2021 and held it in 7 quarters. The position peaked at $967K in Q2 2021. 286 funds tracked by Wall St. Rank hold ARKG as of Q3 2023.

Aviance Capital Partners reported no remaining ARK Genomic Revolution ETF position as of Q3 2023 after selling out during the quarter.
Aviance Capital Partners sold 10,000 ARK Genomic Revolution ETF shares in Q3 2023, an estimated $341K.
Aviance Capital Partners first reported a position in ARK Genomic Revolution ETF in Q1 2021 and held it in 7 quarters.
Aviance Capital Partners's ARK Genomic Revolution ETF position peaked at $967K in Q2 2021.
286 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q3 2023.

Based on Aviance Capital Partners's 13F filing for Q3 2023, filed 7 Nov 2023.